In addition to CD8+ T cells, which are a well-established lymphocyte subset associated with improved clinical outcomes [54,55], B cell markers have also been reported to improve the overall survival (OS) of HNSCC patients [56] and HPV-specific B cell phenotypes have been defined in the HNSCC tumor microenvironment [57]. This evidence concerns the gene CD8A and neoplasm.